Literature DB >> 24020673

In-stent restenosis of drug-eluting stents.

Sa'ar Minha1, Augusto D Pichard, Ron Waksman.   

Abstract

Drug-eluting stents (DES) have emerged as an improved alternative to bare-metal stents by demonstrating reduced rates of restenosis and target lesion revascularization. This emergence has led to the unrestricted use of DES for various indications and lesions, and subsequently revealed DES in-stent restenosis as a novel interventional therapeutic dilemma. Recent insights regarding the patho-physiological processes and therapeutic alternatives have added to the accumulated knowledge regarding the appropriate approach to this phenomenon. This review aims to detail the mechanism and clinical presentation of, and therapeutic strategies for, the treatment of DES in in-stent restenosis.

Entities:  

Mesh：

Year:  2013        PMID： 24020673     DOI： 10.2217/fca.13.45

Source DB:  PubMed          Journal:  Future Cardiol        ISSN： 1479-6678


  7 in total

1.  Paraffin processing of stented arteries using a postfixation dissolution of metallic and polymeric stents.

Authors:  Ilia Fishbein; Tre Welch; David T Guerrero; Ivan S Alferiev; Richard F Adamo; Michael Chorny; Rohit K Gupte; Yanqing Tang; Robert J Levy
Journal:  Cardiovasc Pathol       Date:  2016-08-20       Impact factor: 2.185

2.  Efficacy and safety of low-dose clopidogrel after 12-month dual antiplatelet therapy for patients having drug-eluting stent implantation.

Authors:  Xiao-Dong Zhuang; Ming Long; Cui-Ling Li; Cheng-Heng Hu; Zhi-Ming Du; Xin-Xue Liao
Journal:  J Thorac Dis       Date:  2014-05       Impact factor: 2.895

3.  Plasma levels of miR-143 and miR-145 are associated with coronary in-stent restenosis within 1 year of follow-up after drug-eluting stent implantation.

Authors:  Yuan Yuan; Xiaoxian Liu; Shengyun Hao; Qian He; Zheng Shen
Journal:  Ann Transl Med       Date:  2020-06

4.  Drug-eluting balloons versus new generation drug-eluting stents for the management of in-stent restenosis: an updated meta-analysis of randomized studies.

Authors:  Lei Gao; Ya-Bin Wang; Jing Jing; Ming Zhang; Yun-Dai Chen
Journal:  J Geriatr Cardiol       Date:  2019-06       Impact factor: 3.327

5.  A case of coronary artery disease with rapid progress triggered by stent implantation.

Authors:  Chao Feng; Liang Li; Shudong Xia
Journal:  J Int Med Res       Date:  2020-04       Impact factor: 1.671

6.  lncRNA MALAT1/miR-143 axis is a potential biomarker for in-stent restenosis and is involved in the multiplication of vascular smooth muscle cells.

Authors:  Chen Cao; Wei Zhen; Haibin Yu; Li Zhang; Yiling Liu
Journal:  Open Life Sci       Date:  2021-12-20       Impact factor: 0.938

7.  The Relationships between Polymorphisms in Genes Encoding the Growth Factors TGF-β1, PDGFB, EGF, bFGF and VEGF-A and the Restenosis Process in Patients with Stable Coronary Artery Disease Treated with Bare Metal Stent.

Authors:  Tadeusz Osadnik; Joanna Katarzyna Strzelczyk; Rafał Reguła; Kamil Bujak; Martyna Fronczek; Małgorzata Gonera; Marcin Gawlita; Jarosław Wasilewski; Andrzej Lekston; Anna Kurek; Marek Gierlotka; Przemysław Trzeciak; Michał Hawranek; Zofia Ostrowska; Andrzej Wiczkowski; Lech Poloński; Mariusz Gąsior
Journal:  PLoS One       Date:  2016-03-01       Impact factor: 3.240
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.